<VariationArchive VariationID="195040" VariationName="NM_000203.5(IDUA):c.191_192del (p.Tyr64fs)" VariationType="Deletion" Accession="VCV000195040" Version="10" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-15" DateCreated="2015-06-28" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="192202" VariationID="195040">
      <GeneList>
        <Gene Symbol="SLC26A1" FullName="solute carrier family 26 member 1" GeneID="10861" HGNC_ID="HGNC:10993" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>4p16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="978991" stop="993404" display_start="978991" display_stop="993404" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="972860" stop="987223" display_start="972860" display_stop="987223" Strand="-" />
          </Location>
          <OMIM>610130</OMIM>
        </Gene>
        <Gene Symbol="IDUA" FullName="alpha-L-iduronidase" GeneID="3425" HGNC_ID="HGNC:5391" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>4p16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="986997" stop="1008351" display_start="986997" display_stop="1008351" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="980784" stop="998316" display_start="980784" display_stop="998316" Strand="+" />
          </Location>
          <OMIM>252800</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000203.5(IDUA):c.191_192del (p.Tyr64fs)</Name>
      <CanonicalSPDI>NC_000004.12:987840:AC:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4p16.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="987841" stop="987842" display_start="987841" display_stop="987842" variantLength="2" positionVCF="987840" referenceAlleleVCF="TAC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="981629" stop="981630" display_start="981629" display_stop="981630" variantLength="2" positionVCF="981628" referenceAlleleVCF="TAC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>Y64fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.981629_981630del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.981629_981630del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.987841_987842del" Assembly="GRCh38">
            <Expression>NC_000004.12:g.987841_987842del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008103.1" sequenceAccession="NG_008103" sequenceVersion="1" change="g.5845_5846del">
            <Expression>NG_008103.1:g.5845_5846del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_033042.1" sequenceAccession="NG_033042" sequenceVersion="1" change="g.10595_10596del">
            <Expression>NG_033042.1:g.10595_10596del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_022042.4" sequenceAccession="NM_022042" sequenceVersion="4" change="c.*991_*992del" MANESelect="true">
            <Expression>NM_022042.4:c.*991_*992del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_213613.4" sequenceAccession="NM_213613" sequenceVersion="4" change="c.*991_*992del">
            <Expression>NM_213613.4:c.*991_*992del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000203.5" sequenceAccession="NM_000203" sequenceVersion="5" change="c.191_192del" MANESelect="true">
            <Expression>NM_000203.5:c.191_192del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000194.2" sequenceAccession="NP_000194" sequenceVersion="2" change="p.Tyr64fs">
            <Expression>NP_000194.2:p.Tyr64fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_110313.1" sequenceAccession="NR_110313" sequenceVersion="1" change="n.279_280del">
            <Expression>NR_110313.1:n.279_280del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_134425.4" sequenceAccession="NM_134425" sequenceVersion="4" change="c.576+3286_576+3287del">
            <Expression>NM_134425.4:c.576+3286_576+3287del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277" sequenceAccession="LRG_1277">
            <Expression>LRG_1277:g.5845_5846del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277t1" sequenceAccession="LRG_1277t1">
            <Expression>LRG_1277t1:c.191_192del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1277p1" sequenceAccession="LRG_1277p1" change="p.Tyr64fs">
            <Expression>LRG_1277p1:p.Tyr64fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA275064" DB="ClinGen" />
        <XRef Type="rs" ID="794727240" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000203.5(IDUA):c.191_192del (p.Tyr64fs) AND Hurler syndrome" Accession="RCV000175553" Version="2">
        <ClassifiedConditionList TraitSetID="3230">
          <ClassifiedCondition DB="MedGen" ID="C0086795">Hurler syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-07-21" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.191_192del (p.Tyr64fs) AND not provided" Accession="RCV000724286" Version="4">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2014-09-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.191_192del (p.Tyr64fs) AND Mucopolysaccharidosis type 1" Accession="RCV001249025" Version="7">
        <ClassifiedConditionList TraitSetID="22506">
          <ClassifiedCondition DB="MedGen" ID="C0023786">Mucopolysaccharidosis type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-12-11" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-12-11" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2015-06-28" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11735025</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21480867</ID>
        </Citation>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=IDUA</URL>
        </Citation>
        <DescriptionHistory Dated="2023-12-13">
          <Description>Conflicting classifications of pathogenicity</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-02-01">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2018-08-12">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2018-08-12">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="22506" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7856" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis type 1</ElementValue>
                <XRef ID="MONDO:0001586" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler-Scheie syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Scheie syndrome (former subtype; formerly known as Mucopoly-saccharidosis type V)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-L-Iduronidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IDUA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS I</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10335" />
                <XRef ID="10335" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="579" DB="Orphanet" />
              <XRef ID="C0023786" DB="MedGen" />
              <XRef ID="MONDO:0001586" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3230" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5271" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hurler syndrome</ElementValue>
                <XRef ID="MONDO:0011758" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gargoylism, Hurler Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-H</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS I H</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12559" />
                <XRef ID="12559" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93473" DB="Orphanet" />
              <XRef ID="C0086795" DB="MedGen" />
              <XRef ID="MONDO:0011758" DB="MONDO" />
              <XRef Type="MIM" ID="607014" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1543025" SubmissionDate="2018-07-10" DateLastUpdated="2015-06-28" DateCreated="2015-06-28">
        <ClinVarSubmissionID localKey="461157|OMIM:607014" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000792721" DateUpdated="2015-06-28" DateCreated="2015-06-28" Type="SCV" Version="1" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-07-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/sbjulxjt/counsyl_autosomal_recessive_and_x-linked_classification_criteria_2018_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="4" alternateAllele="T" referenceAllele="TAC" start="981628" stop="981630" variantLength="3" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.3:c.191_192delAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607014" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4282047</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="415376" SubmissionDate="2018-09-19" DateLastUpdated="2018-12-15" DateCreated="2015-06-28">
        <ClinVarSubmissionID localKey="23281_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000227060" DateUpdated="2018-12-15" DateCreated="2015-06-28" Type="SCV" Version="5" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-09-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/ahdynye1/egl_classification_definitions_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="4" alternateAllele="-" referenceAllele="AC" start="981629" stop="981630" variantLength="2" />
            <GeneLocation>NM_000203.3:Ex2</GeneLocation>
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=IDUA</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB4534263</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2805359" SubmissionDate="2023-12-11" DateLastUpdated="2023-12-17" DateCreated="2020-07-19">
        <ClinVarSubmissionID localKey="4ccbb6a3-9ba6-483e-9ae7-6208f26baa96|Orphanet:ORPHA579" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001422948" DateUpdated="2023-12-17" DateCreated="2020-07-19" Type="SCV" Version="3" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The p.Tyr64CysfsTer67 variant in IDUA has not been previously reported in individuals with mucopolysaccharidosis (MPS) but has been identified in 0.0048% (2/41454) of African chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs794727240). Although this variant has been seen in the general population, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID: 195040) as pathogenic by EGL Genetic Diagnostics and as likely pathogenic by Counsyl. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 64 and leads to a premature termination codon 67 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the IDUA gene is an established disease mechanism in autosomal recessive MPS. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive mucopolysaccharidosis. ACMG/AMP Criteria applied: PVS1, PM2 (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000203.4(IDUA):c.191_192del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.12:g.987841_987842delAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA579" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6906750</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5917015" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="17285278|MedGen:C0023786" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003228518" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11735025</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21480867</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 195040). This variant has not been reported in the literature in individuals affected with IDUA-related conditions. This variant is present in population databases (rs794727240, gnomAD 0.01%). This sequence change creates a premature translational stop signal (p.Tyr64Cysfs*67) in the IDUA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IDUA are known to be pathogenic (PMID: 11735025, 21480867).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.981629_981630del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023786" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2805359" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA579" MappingRef="Orphanet">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="415376" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1543025" TraitType="Disease" MappingType="XRef" MappingValue="607014" MappingRef="OMIM">
        <MedGen CUI="C0086795" Name="Hurler syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5917015" TraitType="Disease" MappingType="XRef" MappingValue="C0023786" MappingRef="MedGen">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

